With some 150 human cases of avian flu reported in Asia, resulting in at least 80 deaths, the urgency to stockpile sufficient vaccines to prevent the virus or halt its spread has been mounting. The fear that this flu virus will mutate into a worldwide human pandemic has caused governments and health organizations to begin spending vast sums of money to combat it.
Amid the growing concern, Swiss pharmaceutical Roche's announcement that it will produce an additional 100 million doses of Tamiflu, an antiviral drug developed with Gilead Sciences
While there is a lot of consternation lately about the spread of the H5N1 strain of avian flu, it's unknown whether the virus, currently transmissible to humans only through contact with infected birds, can even make the jump from to direct human-to-human transmission. For thousands of years, migrating birds have regularly spread avian flu viruses without human infection. Thus far, there doesn't appear to be any difference between the H5N1 virus and other strains of avian flu in how they infect people. Consider that millions of fowl have been infected with the virus for the past several years, but only a relatively small number of people have become infected, and fewer still have died. We certainly need to prepare for the potential, but we must also use caution when responding to potential media- or government-inspired hysteria.
Tamiflu is seen as the best current defense against the virus, but that may not always be the case. Viruses develop immunities to drugs when exposed to them over long periods of time. That apparently occurred with the drug amantadine, which was widely distributed in the 1990s but is now considered ineffectual. Some evidence suggests that the virus is developing an immunity to Tamiflu as well; in Thailand, eight of 10 people infected with H5N1 and treated with Tamiflu still died.
That has given new momentum to other companies to produce different treatments and vaccines. GlaxoSmithKline
Small biotech upstarts are also looking for solutions. For example, BioCrystPharmaceuticals
Making the jump from birds to humans is no easy feat, even for fast-mutating viruses like the avian flu. There usually needs to be a third party, like a pig, that is infected simultaneously with human and avian viruses, allowing both to swap parts of their genetic code and infect humans. Even so, the mutation is a difficult process, and it's even harder for the virus to then evolve enough to transmit between humans. Animal husbandry practices in the West generally prevent such occurrences, but in Asia, where fowl and livestock are regularly commingled, the potential is much greater, which helps to explain why most of the cases have surfaced there.
While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about.
Further fine feathered Foolishness:
Fool contributor Rich Duprey does not own any of the stocks mentioned in this article. You can see his holdings here. GlaxoSmithKline is a Motley Fool Income Investor pick. The Motley Fool has a disclosure policy.
More from The Motley Fool
Solar Companies Are Set Up for a Strong Earnings Season
Rising demand and prices for solar panel prices bode well for manufacturers.
Today's Workers Aren't Optimistic About Raises and Promotions, Data Shows
Surprisingly, a large number of workers across the globe think their chances of a pay or title boost are pretty low. Here's how to bust out of that cycle and propel your career forward.
Could These High-Flying Tech Stocks Start Paying a Dividend?
Alphabet, Facebook, and Adobe don't do it yet, but that could change sooner than you think.